On 19 December 2024, the FDA removed tirzepatide from its official drug shortage list, with semaglutide expected to follow in 2025 [3]
Managing these side effects through dietary modifications (such as eating bland, easily digestible foods) and anti-emetic medication if prescribed can help maintain nutritional status
Melanoma Risk The relationship between MT-2 and melanoma is not definitively established, but the theoretical concern is significant: MT-2 stimulates melanocyte proliferation the same cell type that becomes malignant in melanoma At least 4 case reports link MT-2 use to melanoma diagnosis (Hjuler et al., 2014) No long-term safety data exists MT-2 has never completed Phase III trials for tanning However, it's important to note: Case reports cannot establish causation MT-2 users are often the same population that uses tanning beds (an established melanoma risk factor) The FDA-approved MT-1 (afamelanotide), which works through the same MC1R pathway, has not shown melanoma signals in clinical trials Bottom line: The risk is theoretical but plausible
Persistent changes in sexual function, fertility concerns, pelvic pain, or possible hormone symptoms should be evaluated by an appropriate medical clinician
When to See a Doctor Not all lip color changes are pigmentation issues
To ensure a fair comparison and reduce bias, the researchers performed a one-to-one case-control matching